These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29334132)

  • 1. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.
    Nguyen NV; Gralla J; Abbott J; Bruckner AL
    Pediatr Dermatol; 2018 Mar; 35(2):208-212. PubMed ID: 29334132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old.
    Wolosker N; Schvartsman C; Krutman M; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
    Pediatr Dermatol; 2014; 31(1):48-53. PubMed ID: 23627681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].
    Maillard H; Fenot M; Bara C; Célérier P
    Ann Dermatol Venereol; 2011 Oct; 138(10):652-6. PubMed ID: 21978500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
    Schollhammer M; Brenaut E; Menard-Andivot N; Pillette-Delarue M; Zagnoli A; Chassain-Le Lay M; Sassolas B; Jouan N; Le Ru Y; Abasq-Thomas C; Greco M; Penven K; Roguedas-Contios AM; Dupré-Goetghebeur D; Gouedard C; Misery L; Le Gal G
    Br J Dermatol; 2015 Nov; 173(5):1163-8. PubMed ID: 26114588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
    J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
    Artzi O; Loizides C; Zur E; Sprecher E
    Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
    Try C; Messikh R; Elkhyat A; Aubin F; Humbert RP
    Rev Med Liege; 2012 Oct; 67(10):520-6. PubMed ID: 23167161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin.
    Teivelis MP; Wolosker N; Krutman M; Milanez de Campos JR; Kauffman P; Puech-Leão P
    Ann Thorac Surg; 2014 Nov; 98(5):1797-802. PubMed ID: 25173719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxybutynin therapy for generalized hyperhidrosis.
    Tupker RA; Harmsze AM; Deneer VH
    Arch Dermatol; 2006 Aug; 142(8):1065-6. PubMed ID: 16924061
    [No Abstract]   [Full Text] [Related]  

  • 10. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
    Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
    Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.
    Wolosker N; Kauffman P; de Campos JRM; Faustino CB; da Silva MFA; Teivelis MP; Puech-Leão P
    Int J Dermatol; 2020 Jun; 59(6):709-715. PubMed ID: 32301117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers.
    Del Boz J; Millán-Cayetano JF; Blázquez-Sánchez N; de Troya M
    Pediatr Dermatol; 2016 May; 33(3):327-31. PubMed ID: 27122197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary Experience with Transdermal Oxybutynin Patches for Hyperhidrosis.
    Bergón-Sendín M; Pulido-Pérez A; Sáez-Martín LC; Suárez-Fernández R
    Actas Dermosifiliogr; 2016 Dec; 107(10):845-850. PubMed ID: 27497508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of oxybutynin for treating axillary hyperhidrosis.
    Wolosker N; de Campos JR; Kauffman P; Neves S; Munia MA; BiscegliJatene F; Puech-Leão P
    Ann Vasc Surg; 2011 Nov; 25(8):1057-62. PubMed ID: 22023940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
    Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
    J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients.
    Kim WO; Kil HK; Yoon KB; Yoo JH
    Acta Derm Venereol; 2010 May; 90(3):291-3. PubMed ID: 20526549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin in primary hyperhidrosis: A long-term real-life study.
    Almeida ART; Ferrari F; Restrepo MVS; Rocha VB
    Dermatol Ther; 2020 Nov; 33(6):e14344. PubMed ID: 32981151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
    Hebert AA; Glaser DA; Green L; Werschler WP; Forsha DW; Drew J; Gopalan R; Pariser DM
    Pediatr Dermatol; 2019 Jan; 36(1):89-99. PubMed ID: 30451318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of topical agents and oxybutynin as a therapeutic modality for patients with both osmidrosis and hyperhidrosis.
    Varella AYM; Fukuda JM; Teivelis MP; Pinheiro LL; Mendes CA; Kauffman P; Campos JRM; Wolosker N
    Rev Assoc Med Bras (1992); 2018 Feb; 64(2):127-132. PubMed ID: 29641679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.